Login / Signup

Collocation of metformin and dipeptidyl peptidase-4 inhibitor is associated with increased risk of diabetes-related vascular dementia: A single hospital study in Northern Taiwan.

I-Shiang TzengTsung-Han Hsieh
Published in: Expert opinion on investigational drugs (2023)
In this study, patients who received a combination therapy of metformin and DPP-4 inhibitor for DM were at a higher risk of dementia than those who received monotherapy.
Keyphrases
  • combination therapy
  • mild cognitive impairment
  • type diabetes
  • cardiovascular disease
  • healthcare
  • cognitive impairment
  • clinical trial
  • glycemic control
  • weight loss
  • insulin resistance
  • acute care